

application Ser. No. 09/625,770, filed Jul. 26, 2000, now abandoned, which is a continuation of application Ser. No. 09/450,926, filed on Nov. 29, 1999, now abandoned, which is a continuation of application Ser. No. 09/239,443, filed Jan. 28, 1999, now abandoned, which is a continuation of application Ser. No. 09/024,021, filed Feb. 16, 1998, now abandoned, which is a continuation of application Ser. No. 08/787,841, filed Jan. 23, 1997, now abandoned, which is a continuation of application Ser. No. 08/036,316, filed Mar. 24, 1993, now abandoned.

IN THE CLAIMS

Claims 1-27 (cancelled).

28. (new) A therapeutic method for treating a circulatory disorder or circulatory-related disorders, said method comprising administering to a subject susceptible to or afflicted with said disorder a therapeutically effective amount of a compound selected from the group consisting of 1-(2-ethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2-isopropylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-dimethoxyphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2-chloro-6-methylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-dimethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-diethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,4,6-trimethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one; and
a pharmaceutically-acceptable salt thereof.

29. (new) The method of Claim 28 wherein said circulatory disorder or circulatory-related disorders is a cardiovascular disorder.

30. (new) The method of Claim 29 wherein said cardiovascular disorder is hypertension.

31. (new) The method of Claim 29 wherein said cardiovascular disorder is congestive heart failure.

32. (new) The method of Claim 29 wherein said cardiovascular disorder is arteriosclerosis.

33. (new) A therapeutic method for treating glaucoma disorder mediated by angiotensin II receptors, said method comprising administering to a subject susceptible to or afflicted with said disorder a therapeutically effective amount of a compound selected from the group consisting of 1-(2-ethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2-isopropylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-dimethoxyphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2-chloro-6-methylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-dimethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-diethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,4,6-trimethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one; and
a pharmaceutically-acceptable salt thereof.

34. (new) A therapeutic method for treating or preventing surgically-induced disorder, said method comprising administering to a subject susceptible to or afflicted with said disorder a therapeutically effective amount of a compound selected from the group consisting of 1-(2-ethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2-isopropylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-dimethoxyphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2-chloro-6-methylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-dimethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,6-diethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one;
1-(2,4,6-trimethylphenyl)-4-butyl-1,3-dihydro-3-[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-ylmethyl]-2H-imidazol-2-one; and
a pharmaceutically-acceptable salt thereof.

35. (new) The method of Claim 34 wherein said method is for preventing post-angioplasty re-stenosis.

36. (new) The method of Claim 34 wherein said method is for treating coronary hypertrophy arising from aortal stenosis.